Company news
Lionco Pharmaceutical Group Co., Ltd. news in 2026
Lionco Pharmaceutical Group Co., Ltd.'s news releases, calls and decks from 2026, newest first.
(603669)"Lionco Pharmaceutical Group Co., Ltd."Third Indicative Announcement on Redemption at Maturity and Delisting of "Lionco Convertible Bonds"
October 29, 2026
(603669)"Lionco Pharmaceutical Group Co., Ltd."Second Indicative Announcement on Redemption at Maturity and Delisting of "Lionco Convertible Bonds"
October 28, 2026
(603669)"Lionco Pharmaceutical Group Co., Ltd."First Indicative Announcement on Redemption at Maturity and Delisting of "Lionco Convertible Bonds"
October 27, 2026
(603669)"Lionco Pharmaceutical Group Co., Ltd."Report for Q3 2026
October 23, 2026
(603669)"Lionco Pharmaceutical Group Co., Ltd."Announcement on Conversion Results of Convertible Bonds and Share Changes
October 9, 2026
Announcement on Obtaining Drug Registration Certificate for Isavuconazonium Sulfate for Injection by Wholly-owned Subsidiary
September 29, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
September 16, 2026
Announcement on Resolutions of the 12th Meeting of the 5th Board of Directors
August 31, 2026
Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
August 14, 2026
Announcement on Selection of the Subsidiary's Product Huperzine A for Injection in the Inter-Provincial Alliance Centralized Procurement
August 12, 2026
Indicative Announcement on "Lionco Convertible Bonds" Expected to Meet Conditions for Revising Conversion Price
August 3, 2026
Announcement on Abnormal Fluctuations in Stock Trading
July 20, 2026
Semi-annual Performance Forecast for 2026
July 14, 2026
Announcement on Conversion Result of Convertible Bonds and Share Changes
July 2, 2026
Announcement on Follow-up Rating Results of "Lionco Convertible Bonds" in 2026
June 26, 2026
Announcement on No Downward Revision of Conversion Price of "Lionco Convertible Bonds"
June 16, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
June 12, 2026
Announcement on Resignation of Secretary of the Board of Directors and Deputy General Manager
June 10, 2026
Announcement on Early Return of Raised Funds Temporarily Used to Supplement Current Capital
June 9, 2026
Indicative Announcement on Expected Satisfaction of Conversion Price Correction Conditions for ""Lionco Convertible Bonds"
May 19, 2026
Announcement on the Company's and Its Wholly-owned Subsidiaries' Application for Comprehensive Credit Line from Banks in 2026 and Providing Corresponding Guarantee
April 28, 2026
Announcement on Postponing Disclosure of 2025 Annual Report and Report for Q1 2026
April 24, 2026
Announcement on Cancellation of Repurchased Shares Without Adjustment of Conversion Price for Convertible Bonds
April 21, 2026
Announcement on Conversion Result of Convertible Bonds and Share Changes
April 3, 2026
Announcement on the Reply to the Inquiry Letter Regarding Matters Relating to the Earnings Forecast of Lionco Pharmaceutical Group Co., Ltd.
March 24, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
March 5, 2026
Announcement on Changing Signatory Certified Public Accountant
March 2, 2026
Announcement on Release of Pledge of Partial Shares of Controlling Shareholders
February 11, 2026
Announcement on Resolutions of the 6th Meeting of the 5th Board of Directors
January 30, 2026
Earnings Preannouncement for 2025
January 23, 2026